Citigroup has decided to maintain its Neutral rating of Syneos Health SYNH and lower its price target from $70.00 to $55.00.
Shares of Syneos Health are trading down 3.28% over the last 24 hours, at $49.76 per share.
A move to $55.00 would account for a 10.53% increase from the current share price.
About Syneos Health
Syneos is a global contract research and outsourced commercialization organization that provides services to pharmaceutical and biotechnology firms. Its clinical solutions segment offers early- to late-stage clinical trial support that ranges from specialized staffing models to strategic partnerships that oversee nearly all aspects of a drug program, while the company’s commercialization solutions includes outsourced sales, consulting, public relations, and advertising services.
About Analyst Ratings
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish “analyst ratings” for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in Benzinga Pro.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
Source: benzinga.com
/cloudfront-us-east-1.images.arcpublishing.com/pmn/X6WXZ45CTJGKRMHHJYBUZ2TAKA.jpg)
